The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer's disease pathology.
Shun-Fat LauWei WuHiu Yi WongLi OuyangYi QiaoJiahui XuJessica Hiu-Yan LauCarlton WongYuanbing JiangDavid M HoltzmanAmy K Y FuNancy Y IpPublished in: Nature aging (2023)
In Alzheimer's disease (AD), sensome receptor dysfunction impairs microglial danger-associated molecular pattern (DAMP) clearance and exacerbates disease pathology. Although extrinsic signals, including interleukin-33 (IL-33), can restore microglial DAMP clearance, it remains largely unclear how the sensome receptor is regulated and interacts with DAMP during phagocytic clearance. Here, we show that IL-33 induces VCAM1 in microglia, which promotes microglial chemotaxis toward amyloid-beta (Aβ) plaque-associated ApoE, and leads to Aβ clearance. We show that IL-33 stimulates a chemotactic state in microglia, characterized by Aβ-directed migration. Functional screening identified that VCAM1 directs microglial Aβ chemotaxis by sensing Aβ plaque-associated ApoE. Moreover, we found that disrupting VCAM1-ApoE interaction abolishes microglial Aβ chemotaxis, resulting in decreased microglial clearance of Aβ. In patients with AD, higher cerebrospinal fluid levels of soluble VCAM1 were correlated with impaired microglial Aβ chemotaxis. Together, our findings demonstrate that promoting VCAM1-ApoE-dependent microglial functions ameliorates AD pathology.
Keyphrases
- inflammatory response
- neuropathic pain
- lipopolysaccharide induced
- lps induced
- cognitive decline
- high fat diet
- spinal cord
- coronary artery disease
- cell adhesion
- cerebrospinal fluid
- mild cognitive impairment
- transcription factor
- type diabetes
- mouse model
- metabolic syndrome
- adipose tissue
- binding protein
- single molecule
- insulin resistance